gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Phosphodiesterase 7A

Phosphodiesterase, PDE4
The protein encoded by this gene belongs to the cyclic nucleotide phosphodiesterase (PDE) family, and PDE7 subfamily. This PDE hydrolyzes the second messenger, cAMP, which is a regulator and mediator of a number of cellular responses to extracellular signals. Thus, by regulating the cellular concentration of cAMP, this protein plays a key role in many important physiological processes. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Jul 2011] (from NCBI)
Top mentioned proteins: PDE, PDE5, CAN, V1a, HAD
Papers on Phosphodiesterase
Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases.
Wennogle et al., In J Med Chem, Feb 2016
The structure-activity relationships of these polycyclic compounds as phosphodiesterase 1 (PDE1) inhibitors were studied along with their physicochemical and pharmacokinetic properties.
Active Site Metal Occupancy and Cyclic di-GMP Phosphodiesterase Activity of Thermotoga maritima HD-GYP.
Kurtz et al., In Biochemistry, Feb 2016
Up to now the only reported crystal structure of an HD-GYP that also exhibits c-di-GMP phosphodiesterase activity contains a His/carboxylate ligated triiron active site.
Cyclic nucleotide phosphodiesterase isoforms in human basophils and mast cells.
Peachell et al., Eşfahān, Iran. In Int J Immunopathol Pharmacol, Feb 2016
UNASSIGNED: Cyclic nucleotide phosphodiesterase (PDE) exists as multiple molecular forms.
Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study.
Zane et al., Palo Alto, United States. In Pediatr Dermatol, Feb 2016
BACKGROUND: Phosphodiesterase-4 (PDE4) is an emerging target in treating inflammatory skin diseases.
The structure and catalytic mechanism of Human Sphingomyelin Phosphodiesterase like 3a - an acid sphingomyelinase homolog with a novel nucleotide hydrolase activity.
Nordlund et al., Singapore, Singapore. In Febs J, Feb 2016
UNASSIGNED: Human sphingomyelinase phosphodiesterase like 3a (SMPDL3a) is a secreted enzyme that shares a conserved catalytic domain with human acid sphingomyelinase (aSMase), the enzyme carrying mutations causative of Niemann Pick disease.
The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Salonia et al., Milano, Italy. In Expert Opin Drug Saf, Feb 2016
INTRODUCTION: Phosphodiesterase type 5 inhibitors (PDE5Is) are the leading drugs for the treatment of erectile dysfunction (ED), being recommended as a first line treatment by both the European and US urological guidelines.
Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis.
Meyrelles et al., Vila Velha, Brazil. In Curr Pharm Biotechnol, Jan 2016
UNASSIGNED: The usefulness of selective inhibitors of phosphodiesterase 5 (PDE5) is well known, first for the treatment of male erectile dysfunction and more recently for pulmonary hypertension.
Phosphodiesterase4D (PDE4D) - A risk factor for atrial fibrillation and stroke?
Kruuse et al., Glostrup, Denmark. In J Neurol Sci, Jan 2016
Mutations in the gene encoding phosphodiesterase 4D (PDE4D) enzyme are associated with ischemic stroke; however the functional implications of such mutations are not well understood.
[Tyrosyl-DNA Phosphodiesterase 1 Is a New Player in Repair of Apurinic/Apyrimidinic Sites].
Lavrik et al., In Bioorg Khim, Sep 2015
This review is dedicated to one of these proteins, tyrosyl-DNA phosphodiesterase 1 (Tdp1), for which we have recently shown that in addition to its main activity of specific cleavage of the tyrosyl-DNA bond formed via a covalent attachment of topoisomerase 1 (Top1) to DNA, Tdp1 is able to initiate the cleavage of the internal AP sites in DNA and their following repair.
Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Stattin et al., Uppsala, Sweden. In Jama, Jul 2015
IMPORTANCE: The target for the oral erectile dysfunction drugs, phosphodiesterase type 5 (PDE5) inhibitors, is part of a pathway implicated in the development of malignant melanoma.
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.
Kass et al., Baltimore, United States. In Nature, Apr 2015
Cyclic guanosine monophosphate (cGMP) is a second messenger molecule that transduces nitric-oxide- and natriuretic-peptide-coupled signalling, stimulating phosphorylation changes by protein kinase G. Enhancing cGMP synthesis or blocking its degradation by phosphodiesterase type 5A (PDE5A) protects against cardiovascular disease.
Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition.
Garcia-Osta et al., Recife, Brazil. In Mediators Inflamm, 2014
Phosphodiesterase type 5 inhibitors (PDE5-Is) have recently emerged as a potential therapeutic strategy for neuroinflammatory, neurodegenerative, and memory loss diseases.
NADPH oxidase 4 mediates upregulation of type 4 phosphodiesterases in human endothelial cells.
Shukla et al., Bristol, United Kingdom. In J Cell Physiol, 2012
Data demonstrate that upregulation of Nox4 leads to an upregulation of PDE4A, B, and D and increased hydrolysis of cAMP which in turn augments cell replication and angiogenesis.
Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases.
Chung et al., Bethesda, United States. In Cell, 2012
Inhibiting PDE4 with rolipram reproduces all of the metabolic benefits of resveratrol, including prevention of diet-induced obesity and an increase in mitochondrial function, physical stamina, and glucose tolerance in mice.
Positive association of phencyclidine-responsive genes, PDE4A and PLAT, with schizophrenia.
Fukumaki et al., Fukuoka, Japan. In Am J Med Genet B Neuropsychiatr Genet, 2011
These results indicate that PDE4A and PLAT may be susceptibility genes for schizophrenia in the Japanese population.
Interaction between LIS1 and PDE4, and its role in cytoplasmic dynein function.
Houslay et al., Glasgow, United Kingdom. In J Cell Sci, 2011
we have identified a so-far-unknown interaction between LIS1 and PDE4 isoforms, whereby PDE4 can modulate LIS1-dynein complexes and dynein-dependent processes within cells by sequestering LIS1.
Conserved expression and functions of PDE4 in rodent and human heart.
Conti et al., San Francisco, United States. In Basic Res Cardiol, 2011
PDE4 expression is reduced in failing human heart. PDE4 affects local but not global cAMP levels in human cardiomyocytes.
N termini of apPDE4 isoforms are responsible for targeting the isoforms to different cellular membranes.
Kaang et al., Seoul, South Korea. In Learn Mem, 2010
The results of this study suggested that apPDE4s can participate in the regulation of cAMP signaling through specific subcellular localization by means of lipid binding activities.
Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.
Gurney et al., Washington, D.C., United States. In Nat Biotechnol, 2010
Phosphodiesterase 4 (PDE4), the primary cAMP-hydrolyzing enzyme in cells, is a promising drug target for a wide range of conditions.
Sleep deprivation impairs cAMP signalling in the hippocampus.
Abel et al., Philadelphia, United States. In Nature, 2009
Sleep deprivation selectively impaired 3', 5'-cyclic AMP (cAMP)- and protein kinase A (PKA)-dependent forms of synaptic plasticity in the mouse hippocampus, reduced cAMP signalling, and increased activity and protein levels of phosphodiesterase 4 (PDE4), an enzyme that degrades cAMP.
share on facebooktweetadd +1mail to friends